Medical Weight Loss in Thiruvananthapuram GLP-1 Programs: Ozempic, Mounjaro & Wegovy
DermaVue Thiruvananthapuram delivers physician-supervised GLP-1 receptor agonist therapy — tirzepatide (Mounjaro/Zepbound), semaglutide (Ozempic/Wegovy/Rybelsus), and dulaglutide (Trulicity) — structured around the 2023 ADA/EASD consensus and AACE Obesity Algorithm. Our Poojappura clinic serves working professionals, families across Thiruvananthapuram, and international patients from the Maldives. Programs integrate Asian-specific BMI cutoffs (≥23 overweight, ≥27.5 obese per WHO 2004), baseline thyroid/lipase/HbA1c workup, and structured side-effect monitoring. Generic semaglutide is available in India from ₹1,290/month following the March 2026 patent expiry — but safe dose escalation and lab surveillance remain non-negotiable.
✓ No forms · Instant WhatsApp response · Doctor-supervised · From ₹1,290/month
You May Look Healthy — But Your Belly Fat Tells a Different Story
Kerala ranks as India's most diabetic state, yet most patients look and feel "fine." The reason lies in the thin-fat phenotype — a genetic pattern where South Indians accumulate dangerous visceral fat at body weights that Western medicine considers normal.
The South Asian thin-fat phenotype is characterised by higher body fat percentage, greater visceral adiposity, lower lean muscle mass, and earlier pancreatic beta-cell dysfunction at any given BMI compared with Europeans (Yajnik CS, Obesity Reviews 2002; Misra A, Lancet Diabetes Endocrinology 2015). In the landmark Y-Y Paradox published by Dr. C.S. Yajnik and Dr. J.S. Yudkin, two physicians with identical BMI of 22.3 kg/m² had dramatically different DEXA body fat (21.2% vs 9.1%). This biology drove the WHO 2004 Asian-specific recommendation to lower the overweight threshold to BMI 23 and the action threshold to 27.5. The ICMR-INDIAB Study (Lancet Diabetes Endocrinology 2023, N=113,043) confirmed Kerala holds India’s highest diabetes prevalence at 25.5%, with pre-diabetes an additional 15.4% — meaning more than 40% of Kerala adults have dysglycaemia. Visceral adipose tissue — not subcutaneous fat — drives insulin resistance, NAFLD, dyslipidaemia, and premature coronary disease in this population. GLP-1 receptor agonists produce preferential visceral fat reduction and hepatic de-fatting (Gastroenterology 2023), making them mechanistically well-matched to the South Indian metabolic profile.
Kerala diabetes rate — highest among all major Indian states. For educational reference only.
In South Asians carries the same diabetes risk as BMI 30 in Europeans. Indian cutoffs differ from Western standards.
Indian waist cutoffs for men and women respectively — not the Western 102/88 cm. Physician assessment determines individual risk.
Earlier than global average — heart attacks in Kerala strike younger. Early metabolic intervention may help reduce risk.
Your Free Metabolic Health Assessment
Use our physician-designed tools to understand your metabolic risk profile. Results are instant and private — no registration required.
GLP-1 Eligibility Checker
6 quick questions to assess your candidacy. Results shown instantly.
Waist-to-Height Ratio — More Accurate Than BMI for South Indians
Two measurements, instant insight into your metabolic risk.
Metabolic Health Score — Built for Kerala's Body Types
Uses Indian BMI cutoffs, waist measurements, and clinical risk factors.
How Much Does GLP-1 Treatment Cost in Thiruvananthapuram?
Actual 2026 India pricing — generics now available.
When Will You See Results?
Realistic projections based on GLP-1 clinical trial data.
GLP-1 Medications Available at DermaVue Thiruvananthapuram
Your physician determines the appropriate medication during consultation based on your health status, goals, and budget. All medications require physician prescription.
Mounjaro (Tirzepatide)
- Weight loss
- ~20–22% (SURMOUNT-1 trial)
- Mechanism
- Dual GIP + GLP-1 (two pathways)
- Approval
- CDSCO: T2DM + weight management
- Generics
- Patent-protected until 2036–2039
Wegovy (Semaglutide 2.4mg)
- Weight loss
- ~14.9% (STEP 1, NEJM 2021)
- Mechanism
- High-dose GLP-1 receptor agonist
- Approval
- CDSCO: specifically for weight management
- Note
- Generic semaglutide now available from ₹1,290
Ozempic / Generic Semaglutide
- Weight loss
- ~12–15%
- Mechanism
- GLP-1 receptor agonist
- Approval
- CDSCO: T2DM; off-label for weight loss
- Generic launch
- March 20, 2026 — patent expired
| Feature | Mounjaro | Wegovy | Generic Semaglutide |
|---|---|---|---|
| Average weight loss | 20–22% | ~14.9% | ~12–15% |
| Mechanism | GIP + GLP-1 | GLP-1 only | GLP-1 only |
| CDSCO weight approval | T2DM + weight | ✓ Weight only | T2DM only |
| Monthly cost (India) | ₹14,000–27,500 | From ₹5,660 (0.25 mg) | ₹1,290–5,000 |
| Generic available | ✗ Until 2036 | ✗ Branded only | ✓ March 2026 |
| DermaVue available | ✓ Preferred | ✓ Available | ✓ Available |
Physician prescription required for all medications. Individual results vary based on medication response, dietary compliance, and metabolic profile.
Breaking: Generic Semaglutide Launched in India — March 20, 2026
Prices collapsed from ₹5,660 branded to ₹1,290/month generic. Medical supervision is still essential for safe, effective outcomes.
What Changed
- Natco, Zydus, Sun Pharma, Glenmark, Dr. Reddy's generics now available
- Price drop: branded ₹5,660+ → generic ₹1,290/month (Natco/Glenmark vials)
- Pre-filled pen versions: ₹3,600–₹5,000/month
- Mounjaro remains patent-protected (no generics until 2036)
Why Supervision Still Matters
- Generic vials require trained injection technique
- Dose titration must be supervised — incorrect dosing causes severe nausea
- Lab monitoring (thyroid, lipase, HbA1c) is required
- CDSCO issued a safety advisory alongside generic launch
- Side effects management requires physician access
- 28% of India's medicines are counterfeit — verify your source
The semaglutide patent expired in India on March 20, 2026, triggering immediate launches from 50+ pharmaceutical manufacturers including Natco (₹1,290), Glenmark (₹1,300–₹1,760), Dr. Reddy's Obeda (₹4,200), and Sun Pharma Noveltreat (₹3,600–₹8,000). Tirzepatide (Mounjaro) remains under Eli Lilly's patent protection until approximately 2036–2039, with no generic entry expected before then. CDSCO simultaneously issued a safety advisory urging physician supervision for all GLP-1 receptor agonist use, citing risks of unsupervised dose escalation.
The DermaVue SuperHuman Program
Injection alone is insufficient metabolic care. Published analyses of the STEP trials show that 25–39% of total weight lost during GLP-1 therapy is lean mass when resistance training and protein intake are not structured (Prado CM et al., The Lancet 2024). Our 4-pillar protocol is designed to preserve lean body mass, optimise HbA1c and visceral fat reduction, and maintain losses after de-escalation.
Medical Evaluation & Body Composition
- Comprehensive metabolic screening
- Body composition analysis (fat vs muscle)
- Lab panel: HbA1c, thyroid, lipase, liver, lipids
- Trichoscopy for hair health baseline
Physician-Prescribed Medication Protocol
- Medication selection: health profile, budget, target
- Dose escalation schedule (minimise side effects)
- CDSCO-compliant prescription documentation
- Monthly monitoring and dose optimisation
Kerala Cuisine Nutrition Plan
- Dietitian-designed for Kerala food culture
- Puttu, appam, Kerala fish curry — NOT banned
- High-protein adaptations of traditional meals
- Festival/Onam/wedding navigation strategies
Movement & Lifestyle Integration
- Compatible with demanding working-professional schedules
- 30-min lunch-hour effective programmes
- Adaptations for AC-office and sedentary workers
- Sleep optimisation for cortisol/weight regulation
Am I a Candidate for GLP-1 Treatment?
Our physicians conduct comprehensive screening before prescribing any medication. Not everyone is a candidate — safety comes first.
Good Candidates
Who Should NOT Use GLP-1
⚕️ Medical Disclaimer: This information is for educational purposes only. Only your physician can determine GLP-1 eligibility after a complete medical assessment. DermaVue conducts comprehensive screening before any prescription.
Meet Your Doctors at DermaVue Thiruvananthapuram
Dr. Sarath Chandran
Dr. Sarath Chandran, MBBS, MD (DVL), is the clinical lead for the SuperHuman Medical Weight Loss & Longevity Program at DermaVue. He oversees GLP-1-based therapies, medication optimisation, and safe insulin de-escalation, working closely with dietitians to ensure patient safety and sustainable results.
“Obesity is a chronic, relapsing neuro-endocrine disease — not a failure of willpower. GLP-1 therapy corrects the underlying satiety and reward signalling; our job is to make the pharmacology safe, the nutrition sustainable, and the lean mass protected. That’s the difference between weight loss and metabolic health.”
Dr. Rejeesh Menon
Dr. Rejeesh Menon, MD (WSU, USA), is the co-founder and Medical Director of DermaVue. He provides medical oversight for all weight loss protocols, ensures international safety standards, and integrates evidence from US clinical practice into Kerala's metabolic health programmes. The SuperHuman Program's dermatology integration — monitoring for hair loss and skin laxity during rapid weight loss — reflects his vision of holistic metabolic care.
Transparent Pricing — No Hidden Costs
Exact pricing depends on medication choice, dose, and programme duration. WhatsApp us for a personalised quote after your initial assessment.
- Generic semaglutide included
- Dietitian support
- Monthly physician review
- Basic lab monitoring
- Mounjaro or Wegovy included
- Dietitian support
- Fortnightly physician review
- Full metabolic panel
- Body composition tracking
- All medications available
- Advanced metabolic monitoring
- Dermatology integration
- Priority access
- Extended support hours
Medication alone now available from ₹1,290/month with physician supervision at DermaVue
Prices include medication, consultation, monitoring, and dietitian support. Exact pricing varies by medication choice, dose, and programme duration. EMI options available.
DermaVue Thiruvananthapuram — Accessible From Across TVM
- Address
- TC 42, 3003-2, Poojappura Main Rd, Kesari Nagar, Poojapura, Chengalloor, Thiruvananthapuram, Kerala 695012
- Phone
- +91 8330860007
- Message Us on WhatsApp
- tvm@dermavue.com
- Hours
- Mon–Sat: 9 AM–8 PM | Sun: 10 AM–5 PM
- Consultation
- ₹300 Initial Consultation
Medical Weight Loss and GLP-1 Therapy at DermaVue
Frequently Asked Questions — Medical Weight Loss in Thiruvananthapuram
Can I get Ozempic or Mounjaro for weight loss at DermaVue Thiruvananthapuram?
Is generic semaglutide available in Thiruvananthapuram? How much does it cost?
What is the difference between Mounjaro and Ozempic?
Am I eligible for GLP-1 treatment at DermaVue Thiruvananthapuram?
Why does DermaVue — a skin clinic — offer weight loss treatment?
Kerala has the highest diabetes rate in India. Is this related to belly fat?
How long does the weight loss program take? When will I see results?
Can I continue eating Kerala food during the program?
Do GLP-1 medications cause hair loss or skin changes?
Is GLP-1 treatment available for Maldives patients at DermaVue TVM?
Medical Disclaimer: This information is educational and does not constitute medical advice. Individual results vary. All treatments require medical consultation. GLP-1 medications are prescription-only and require physician supervision. Ozempic, Wegovy, and Mounjaro are registered trademarks of their respective manufacturers. DermaVue provides these medications through licensed pharmaceutical channels only. Content reviewed by Dr. Sarath Chandran, MD DVL.
Book Your SuperHuman Program Consultation in Thiruvananthapuram
₹300 Initial Consultation · Physician-Supervised · Same-Week Appointments · Generic semaglutide from ₹1,290/month
📍 TC 42, 3003-2, Poojappura Main Rd, Kesari Nagar, Poojapura, Chengalloor, Thiruvananthapuram, Kerala 695012 | 📧 tvm@dermavue.com